Literature DB >> 25045804

Therapeutic responses to different anti-Trypanosoma cruzi drugs in experimental infection by benznidazole-resistant parasite stock.

Sérgio Caldas1, Ivo Santana Caldas1, Alzira Batista Cecílio2, Lívia DE Figueiredo Diniz1, André Talvani1, Isabela Ribeiro3, Maria Terezinha Bahia1.   

Abstract

SUMMARY This study describes the role of parasite clearance time induced by benznidazole, fexinidazole and posaconazole treatments upon mice infection with a benznidazole-resistant Trypanosoma cruzi strain in the pathological outcomes. Trypanosoma cruzi-infected mice were treated with different drugs and parasite clearance time was detected by blood and tissue qPCR, to determine the dynamic relationship between the efficacy of the treatments and the intensity of heart lesion/serum inflammatory mediators. Our results indicate that anti-T. cruzi treatments were able to reduce parasite replication and consequently induce immunomodulatory effects, where the degree of the immunopathology prevention was related to the time of parasite clearance induced by different treatments. Nevertheless, in benznidazole and posaconazole treatments, parasite rebounding was detected with parasitism reaching levels similar to infected and non-treated mice; the time for parasitic rebound being earlier among benznidazole-treated mice. In parallel, an increase of cardiac lesions and plasma chemokine levels was also detected and was more accentuated in benznidazole-treated animals. Interestingly, in the presence of parasitological cure (fexinidazole treatment), basal levels of these inflammatory mediators were evidenced as well as an absence of cardiac inflammation or fibrosis. Overall, our data indicate that all treatments have positive effects on the clinical evolution of T. cruzi infection, with success in preventing cardiac alterations being drug-dependent.

Entities:  

Year:  2014        PMID: 25045804     DOI: 10.1017/S0031182014000882

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  6 in total

1.  Lychnopholide in Poly(d,l-Lactide)-Block-Polyethylene Glycol Nanocapsules Cures Infection with a Drug-Resistant Trypanosoma cruzi Strain at Acute and Chronic Phases.

Authors:  Renata Tupinambá Branquinho; Carlos Geraldo Campos de Mello; Maykon Tavares Oliveira; Levi Eduardo Soares Reis; Paula Mello de Abreu Vieira; Dênia Antunes Saúde-Guimarães; Vanessa Carla Furtado Mosqueira; Marta de Lana
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

2.  Detection and Quantification of Viable and Nonviable Trypanosoma cruzi Parasites by a Propidium Monoazide Real-Time Polymerase Chain Reaction Assay.

Authors:  Beatriz Cancino-Faure; Roser Fisa; M Magdalena Alcover; Teresa Jimenez-Marco; Cristina Riera
Journal:  Am J Trop Med Hyg       Date:  2016-05-02       Impact factor: 2.345

3.  Curcumin Enhances the Anti-Trypanosoma cruzi Activity of Benznidazole-Based Chemotherapy in Acute Experimental Chagas Disease.

Authors:  Rômulo Dias Novaes; Marcus Vinicius Pessoa Sartini; João Paulo Ferreira Rodrigues; Reggiani Vilela Gonçalves; Eliziária Cardoso Santos; Raquel Lopes Martins Souza; Ivo Santana Caldas
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

Review 4.  Advances and Challenges in Viability Detection of Foodborne Pathogens.

Authors:  Dexin Zeng; Zi Chen; Yuan Jiang; Feng Xue; Baoguang Li
Journal:  Front Microbiol       Date:  2016-11-22       Impact factor: 5.640

Review 5.  Revisiting the Posttherapeutic Cure Criterion in Chagas Disease: Time for New Methods, More Questions, Doubts, and Polemics or Time to Change Old Concepts?

Authors:  Marta de Lana; Olindo Assis Martins-Filho
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

6.  Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice.

Authors:  Lívia de Figueiredo Diniz; Ana Lia Mazzeti; Ivo Santana Caldas; Isabela Ribeiro; Maria Terezinha Bahia
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.